AstraZeneca PLC (STO:AZN)
Sweden
· Delayed Price · Currency is SEK 1,505.00
+5.00 (0.33%)
Aug 15, 2025, 5:29 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.33
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
2,329.06B SEK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.97B |
| Sectra AB | 3.31B |
| Getinge AB | 35.50B |
| Medicover AB | 25.22B |
| Camurus AB | 2.27B |
| Asker Healthcare Group AB | 15.88B |
| BioArctic AB | 1.52B |
| AddLife AB | 10.44B |
AstraZeneca News
- 19 hours ago - FLUMIST (Influenza, Vaccine Live, Intranasal), the nation's only nasal spray flu vaccine, now available for home delivery - Benzinga
- 1 day ago - George Soros Exits AstraZeneca PLC, Impacting Portfolio by -3.98% - GuruFocus
- 2 days ago - The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact - PRNewsWire
- 3 days ago - UK Government, Eli Lilly Partner To Target Obesity Health Gaps - Benzinga
- 4 days ago - AstraZeneca: Great Portfolio, But Not A Great Price - Seeking Alpha
- 6 days ago - Melrose boss soars to top of the Footsie pay league - This is Money
- 8 days ago - Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG) - Benzinga
- 10 days ago - SOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlook - Seeking Alpha